Cosmos Health Inc.
Cosmos Health Inc. (COSM): 33 pipeline candidates · 7 upcoming catalysts · ~35 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
35.4 months
D/E 2.15 · 15% dilution
Lead: Phase 3
33 candidates
7 upcoming, next in ~469d
9 buys · 0 sells (180d)
A transparent, data-derived signal for Cosmos Health Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$15.3M
Cash
$2.2M
Quarterly Burn
$1.1M
Runway
35.4 mo
Revenue
$17.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (33 candidates)
| Drug | Phase |
|---|---|
| 250 nutritional supplements (R&D agreement) | — |
| Asparaginase Erwinia chrysanthemi | Phase 3 |
| Bleomycin Sulfate | Phase 3 |
| Blinatumomab | Phase 3 |
| Brentuximab Vedotin | Phase 3 |
| C-DERM | — |
| C-SEPT | — |
| Calaspargase Pegol | Phase 3 |
| CCX0722 | Preclinical |
| Cytarabine | Phase 3 |
Showing 10 of 33 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
22
Total value held
$584K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 390,500 | $124K |
| citadel advisors llc | 336,606 | $107K |
| geode capital management, llc | 318,111 | $101K |
| vanguard capital management llc | 280,014 | $89K |
| blackrock, inc. | 267,797 | $85K |
| vanguard fiduciary trust co | 95,735 | $30K |
| state street corp | 45,243 | $14K |
| xtx topco ltd | 40,477 | $13K |
| northern trust corp | 20,554 | $7K |
| susquehanna international group, llp | 17,734 | $6K |
Showing top 10 of 22 institutional holders of Cosmos Health Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cosmos Health Inc.'s pipeline?
Cosmos Health Inc. (COSM) has 33 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cosmos Health Inc.'s next catalyst?
Cosmos Health Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient" — expected September 30, 2027.
What is Cosmos Health Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cosmos Health Inc. has approximately 35.4 months of cash runway.
What is Cosmos Health Inc.'s market capitalization?
Cosmos Health Inc.'s market capitalization is approximately $15.3M.
Who is the CEO of Cosmos Health Inc.?
Mr. Grigorios Siokas is the chief executive officer of Cosmos Health Inc. (COSM).
Get the full picture on Cosmos Health Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.